Biomarker set for identifiying a severe form of cancer

Breast cancer has been recognized as a heterogeneous

disease that consists of different intrinsic subtypes, including hormone receptor positive breast cancer (also known as luminal breast cancer), which accounts for 70-80% of newly diagnosed breast tumors. The histologic grade of luminal breast cancer is often determined by semi-quantitative methods describing morphologic features related to the differentiation states of the tumor specimen, ranging from well differentiated “grade 1” tumors, through intermediate differentiation (“grade 2”) to poorly differentiated “grade 3” tumors. Breast tumors characterized as luminal “grade 3” generally respond well to chemotherapeutic treatments, whereas patients with luminal “grade 1” tumors would be overtreated. In order to make a clear-cut classification of luminal breast cancer as either “grade 1” (= low risk) or “grade 3” (= high risk) tumors, DKFZ researchers have developed a 3-protein marker set.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Distance learning can improve women’s access to vocational training as animal health care practitioners in Nepal. Image Credit: Heifer International

Hybrid Job Training Boosts Women’s Participation in Nepal

Globally, women’s workforce participation is about 25% lower than men’s, often due to barriers such as domestic responsibilities and cultural norms. Vocational training can increase employment opportunities, but women may…

CO2release increase under repeated drying-rewetting cycles (DWCs). Image Credit: Suzuki, Nagano et al., 2025 SOIL

Drying and Rewetting Cycles Boost Soil CO2 Emissions

Niigata, Japan – The amount of carbon dioxide (CO2) released by microbial decomposition of soil organic carbon on a global scale is approximately five times greater than the amount of…

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers. Oregon State's Olena Taratula and collaborators including OSU postdoctoral researcher Babak Mamnoon and Maureen Baldwin, a physician at Oregon Health & Science University, designed a type of drug nanocarrier known as a polymersome to specifically target a protein in choriocarcinoma cells. Depicted is a polymersome with its methotrexate cargo. Illustration by Parinaz Ghanbari. Image Credit: Parinaz Ghanbari

Improved Treatment Method for Rare Pregnancy-Related Cancer

PORTLAND, Ore. – A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other…